CoreValve TAVR (29mm) via Percutaneous Femoral Access – Oct 2014

A 76 year-old female with H/O multiple PCI’s and metastatic breast cancer presented with progressive symptomatic severe aortic stenosis, confirmed on cath with AVA 0.6 sq cm. TTE revealed severe AS, peak/mean aortic gradient = 64/48 mmHg, AVA = 0.6 sq cm, aortic peak velocity = 4.2 m/sec and LVEF 60%. CT angio showed minimum diameters of 0.8 x 0.8 cm for Right and 0.8 x 0.7 cm for the Left common femoral arteries and aortic annulus of 2.1 x 2.7 cm (average 2.4). The STS risk mortality is 4.2 and the Logistic Euroscore mortality is 11.7. Patient was determined to be extreme risk for surgical AVR due to metastatic cancer (responding to chemotherapy) with projected life expectancy of 2-3 years. Patient is now planned for CoreValve TAVR (29mm) via percutaneous femoral access under conscious sedation.



Leave a Reply

Your email address will not be published.*

Warning: Invalid argument supplied for foreach() in /home/ on line 1080

Yes, I would like to receive emails from Mount Sinai Hospital. Sign me up!

By submitting this form, you are consenting to receive marketing emails from: Mount Sinai Hospital, One Gustave L. Levy Place, Box, New York, NY, 10029, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact